New research collaboration and licensing agreement with Certest Biotec

Barcelona and San Mateo de Gállego (Zaragoza), Spain.

Today, we announced a strategic research collaboration and licensing agreement with Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma. Through this collaboration, we will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.

The collaboration combines Certest’s integrated mRNA and Lipid Nanoparticle Platform with our expertise in medical dermatology research and clinical development.

“The collaboration with Certest Biotec is aligned with our innovation strategy and supports our commitment to advancing a differentiated pipeline and developing novel therapies in medical dermatology that address unmet patient needs,” said Karl Ziegelbauer, Chief Scientific Officer at Almirall.

“This collaboration marks an important milestone for Certest and further validates the strength of our integrated mRNA and lipid nanoparticle platform,” said Nelson Fernandes, CEO of Certest. “Partnering with Almirall allows us to apply our technology to indications with significant unmet medical needs while reinforcing our commitment to enabling the next generation of RNA-based medicines.”